Genomic differences related to the immune system may play a key role in the early development of lung cancer. That finding, published, in Nature Communications, reveals potential for developing new therapeutics that could boost immune activity to prevent or halt progression of the disease, says the study's senior author. The newly identified genomic differences can be detected in normal airway tissue before any precancerous activity begins, which could potentially help physicians screen and monitor smokers who are at the highest risk of lung cancer.
More people die of lung cancer than from colon, breast, and prostate cancers combined--in the United States alone, lung cancer kills about 143,000 people each year. Worldwide, the number of people with the disease remains high and is growing in certain regions, and among women. In China, for example, 730,000 new cases of lung cancer were reported in 2015 and the number is expected to rise.
"The lung undergoes many changes prior to the development of [full-blown] lung cancer, so we have an opportunity to leverage those changes to both identify people at high risk for lung cancer and to intercept the disease process," says the lead and corresponding author of the Nature Communications study.
The new findings have identified four different genomic subtypes among current and former cigarette smokers who develop precancerous lesions. In people with the most problematic subtype, their immune response is impaired, says the senior author."That's one of the things that tumors do--prevent the immune system from attacking them. We think precancer cells might do that as well," the senior author says. "This opens up the opportunity to come in and find a way to train the immune system to eradicate those lesions."
In the study, scientists used bronchoscopes to take biopsies of precancerous lung lesions in current and former smokers, following the study participants over several years to see if their lesions progressed toward lung cancer or not. They identified biological changes within the lesions that indicated a higher risk of progression and showed that those lesions had reduced activity of genes related to certain kinds of immune cells.
The Proliferative subtype is enriched with bronchial dysplasia and exhibits up-regulation of metabolic and cell cycle pathways. A Proliferative subtype-associated gene signature identifies subjects with Proliferative PMLs from normal-appearing uninvolved large airway brushings with high specificity. In progressive/persistent Proliferative lesions expression of interferon signaling and antigen processing/presentation pathways decrease and immunofluorescence indicates a depletion of innate and adaptive immune cells compared with regressive lesions.
"This is an example where academia does the very basic discovery science--finding patients that have these early precancer lesions, biopsying them, and doing very deep molecular profiling, and the bioinformatics analysis," says the senior author. Then, from those academic findings, "industry can look at the data and figure out how to develop a therapeutic that will leverage that insight, that would reactivate the immune system to intercept the precancerous lesions from progressing to invasive lung cancer."
In addition to its other findings, the new study suggests that changes in aggressive precancerous lesions could be detected by "brushing," using a flexible brush to gather cells from the airway through the catheter of a bronchoscope, which is a much less invasive procedure than a traditional lung or airway biopsy.
"Normal-appearing cells in the airway can still show you the genomic signature," says the corresponding author. "It's early days, but maybe one day [we] could develop a simpler test to find someone who is incubating a lung cancer and [we'd] know who to treat to intercept lung cancer."
http://www.bu.edu/today/2019/iimmune-system-boost-could-prevent-lung-cancer/
https://www.nature.com/articles/s41467-019-09834-2
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fmolecular-subtyping&filter=22
Immune alterations associated with progression of lung cancer
- 1,296 views
- Added
Edited
Latest News
Metabolic rewiring promotes…
By newseditor
Posted 18 Apr
A drug to prevent flu-induc…
By newseditor
Posted 18 Apr
New origin of deep brain waves
By newseditor
Posted 17 Apr
Starving cells hijack prote…
By newseditor
Posted 17 Apr
Miniature battery-free epid…
By newseditor
Posted 17 Apr
Other Top Stories
Genetic markers of type 2 diabetes in East Asians
Read more
Artificial Intelligence (AI) for cardiac diagnostics
Read more
3D imaging method to identify sperm cells moving at a high speed
Read more
How does the brain link events to form a memory?
Read more
Circadian network neurons integrate sensory input
Read more
Protocols
MemPrep, a new technology f…
By newseditor
Posted 08 Apr
A tangible method to assess…
By newseditor
Posted 08 Apr
Stem cell-derived vessels-o…
By newseditor
Posted 06 Apr
Single-cell biclustering fo…
By newseditor
Posted 01 Apr
Modular dual-color BiAD sen…
By newseditor
Posted 31 Mar
Publications
How does the microbiota con…
By newseditor
Posted 18 Apr
The integrated stress respo…
By newseditor
Posted 18 Apr
The immunobiology of herpes…
By newseditor
Posted 17 Apr
Circulating microbiome DNA…
By newseditor
Posted 17 Apr
Spindle oscillations in com…
By newseditor
Posted 17 Apr
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar